Purpose To demonstrate the feasibility of continuous infusion of meropenem–vaborbactam
to optimize the treatment of carbapenem-resistant Enterobacterales. Methods Report of a …

Aim: Infections by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae
represent a major challenge because of limited treatment strategies. New β-lactam/β …

Abstract Background Carbapenem-resistant Enterobacteriaceae (CRE), especially for
carbapenemase-producing Enterobacteriaceae (CPE), is an emerging cause that pose a …

Background Meropenem-vaborbactam (MV) is a new β-lactam-β-lactamase inhibitor
combination that restores the potency of meropenem in Klebsiella pneumoniae …

Background. We evaluated the activity of meropenem (MER)±RPX7009 (RPX), a serine-β-
lactamase inhibitor (BLI) tested against contemporary isolates of Enterobacteriaceae (ENT) …

Dose optimization is required to increase carbapenem's efficacy against carbapenemase-
producing isolates. Four clinical Klebsiella pneumoniae isolates were used: one susceptible …

Background: Gram-negative bacterial resistance to antibiotics is of increasing concern.
Carbapenem resistance among strains of Klebsiella pneumoniae is a relatively new …

Purpose: Optimal treatment regimens are yet to be established for carbapenemase-
producing Enterobacteriaceae (CPE). We assessed the in vitro efficacy of meropenem …

Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a
cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella …

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including
Carbapenem-Resistant and Carbapenemase-Producing I Page 1 Meropenem-Vaborbactam Activity …